Special Procedures Core: A Special Procedures Core will be set up to provide specialized services required by various investigators of the Program Project Grant. The Special Procedures Core will a) continue the services provided by the current PPG Tissue Culture Core and b) evaluate new patients for possible defects in their GH peptide, IGF-I peptide, GH binding protein, and/or tissue responsiveness to IGF-I utilizing procedures established in Project 2 of the current PPG. The culture facility will continue to establish fibroblast strains (est. 12/y) from selected short stature patients with possible defects in their GH/IGF-I tissue responsiveness. Various cell strains will be cultured for the experiments proposed in Projects 2, 4, and 5. Project 2: Methods were developed in the PPG for evaluating the receptor reactivity of the GH and of the IGF-I present in patients' sera, the level of circulating GH-BP, and the IGF-I responsiveness of patients' fibroblasts. These methods provide more complete characterization of the GH/IGF-I status of short stature patients and identify those patients who should receive more in depth investigation by the appropriate PPG project. It is proposed that the Special Procedures Core assume responsibility for these evaluations of new short stature patients. The receptor reactivity of serum GH and IGF-I is determined from the ratio of their reactivity in a receptor assay as compared to reactivity in an IRMA assay. The level of serum GH binding protein is measured by gel filtration separation of bound 125I hGH. The IGF-i responsiveness of patient fibroblast is evaluated with IGF-I dose assays for stimulation of fibroblast uptake of AIB. It is estimated that 20-30 short stature patients will be evaluated by the core annually with selected tests being performed based upon the patient's serum GH and IGF-I levels. These evaluations will also be performed as needed for subjects under the study by Project 8 which is investigating regulation of fetal growth.

Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
1991
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Umayahara, Y; Billiard, J; Ji, C et al. (1999) CCAAT/enhancer-binding protein delta is a critical regulator of insulin-like growth factor-I gene transcription in osteoblasts. J Biol Chem 274:10609-17
Umayahara, Y; Ji, C; Centrella, M et al. (1997) CCAAT/enhancer-binding protein delta activates insulin-like growth factor-I gene transcription in osteoblasts. Identification of a novel cyclic AMP signaling pathway in bone. J Biol Chem 272:31793-800
Mittanck, D W; Kim, S W; Rotwein, P (1997) Essential promoter elements are located within the 5' untranslated region of human insulin-like growth factor-I exon I. Mol Cell Endocrinol 126:153-63
Pike, L J; Casey, L (1996) Localization and turnover of phosphatidylinositol 4,5-bisphosphate in caveolin-enriched membrane domains. J Biol Chem 271:26453-6
Rotwein, P; Bichell, D P; Kikuchi, K (1993) Multifactorial regulation of IGF-I gene expression. Mol Reprod Dev 35:358-63;discussion 363-4
Bichell, D P; Rotwein, P; McCarthy, T L (1993) Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblast cultures: evidence for transcriptional control. Endocrinology 133:1020-8
Daughaday, W H; Trivedi, B (1992) Heterogeneity of serum peptides with immunoactivity detected by a radioimmunoassay for proinsulin-like growth factor-II E domain: description of a free E domain peptide in serum. J Clin Endocrinol Metab 75:641-5
Daughaday, W H; Trivedi, B (1992) Measurement of derivatives of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia. J Clin Endocrinol Metab 75:110-5
Kim, S W; Lajara, R; Rotwein, P (1991) Structure and function of a human insulin-like growth factor-I gene promoter. Mol Endocrinol 5:1964-72
Daughaday, W H; Trivedi, B (1991) Clinical aspects of GH binding proteins. Acta Endocrinol (Copenh) 124 Suppl 2:27-32

Showing the most recent 10 out of 12 publications